sasaconnect.blogg.se

Medications with narrow therapeutic window
Medications with narrow therapeutic window





  1. Medications with narrow therapeutic window manuals#
  2. Medications with narrow therapeutic window software#

As a result, many physicians feel overwhelmed and question the safety of multiple drug regimens. More than 30 medications are introduced each year, and physicians receive frequent mailings about newly discovered drug interactions. As a result, the pharmacist generally consults with the prescribing physician. However, these programs tend to “flag” all interactions, making it difficult for the pharmacist to interpret clinical significance.

Medications with narrow therapeutic window software#

Most pharmacies have drug-interaction software programs with their dispensing package. Recognizing drug interactions is a daily challenge for family physicians, and remembering all potential interactions has become virtually impossible.

Medications with narrow therapeutic window manuals#

Regularly updated manuals of drug interactions and CD-ROM–formatted programs are useful office references. Many other drugs, act as precipitants or objects, and a number of drugs act as both. Object drugs in common use include warfarin, fluoroquinolones, antiepileptic drugs, oral contraceptives, cisapride and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Drugs with a narrow therapeutic range or low therapeutic index are more likely to be the objects for serious drug interactions. Nonsteroidal anti-inflammatory drugs, antibiotics and, in particular, rifampin are common precipitant drugs prescribed in primary care practice. Precipitant drugs modify the object drug's absorption, distribution, metabolism, excretion or actual clinical effect. Multiple drug regimens carry the risk of adverse interactions. Consequently, it is no longer practical for physicians to rely on memory alone to avoid potential drug interactions. A large number of drugs are introduced every year, and new interactions between medications are increasingly reported.







Medications with narrow therapeutic window